Reference | Patient demographics: | Description of matched pairs | Synchronous/metachronous/metastases, n:n | Molecular marker assessment technique | Mutation frequency,c n/N (%) | Concordance, n/N (%) | |||
---|---|---|---|---|---|---|---|---|---|
(i) Median age (range), years | N | Tumour sample storage form | Primary | Metastatic: n | |||||
(ii) Gender, n/N (%) male | Histological subtype: n | Time between primary and metastatic tumour sample collection b | |||||||
(iii) Ethnicity [countrya] | |||||||||
(iv) Smoking status, n/N (%) | |||||||||
Assessment of KRAS molecular marker | |||||||||
Alsdorf et al. [55] | (i) N/A | 19 | FFPE | Lung | Lymph node | N/A | ARMS method with direct sequencing after enrichment of tumour cells by laser capture microdissection | 19/19 (100) vs 19/19 (100) | 19/19 (100) |
(ii) N/A | N/A | ||||||||
(iii) [Germany] | |||||||||
(iv) N/A | |||||||||
Badalian et al. [57] | (i) N/A (47–76) | 11 | FFPE | Lung | Bone | N/A | RFLP-PCR | 3/11 (27) vs 3/11 (27) | 7/11 (64) |
(ii) 8/11 (72.7) | N/A | ||||||||
(iii) [Hungary] | |||||||||
(iv) N/A | |||||||||
Cortot et al. [3] | (i) [Mean] 59.7 (39–73) | 21 | FFPE | Lung | Brain: 13 | 6:15 | Direct sequencing and mutant-enriched PCR | [Direct sequencing] | [Direct sequencing] |
(ii) 6/21 (28.6) | ADC: 16 | Lung: 4 | N/A | 3/21 (14) vs 4/21 (19) | 15/21 (71) | ||||
(iii) [France] | SSC: 2 | Bone: 2 | [Mutant-enriched PCR] | ||||||
(iv) N/A | LCC: 2 | Soft tissue: 2 | 17/21 (81) | ||||||
Holst et al. [58] | (i) [Mean] 55.7 (2–72) | 10 | N/A | Lung | Synchronous/metachronous intrathoracic metastases | Numbers not specified | Topographic genotyping and direct sequencing | 6/10 (60) vs 6/10 (60) | 10/10 (100) |
(ii) Male:female ratio, 1:1 | N/A | ||||||||
(iii) [USA] | |||||||||
(iv) 70 % of patients had a positive smoking history | |||||||||
Li et al. [56] | (i) 60 (36–80) | 15 | FFPE | Lung | Various | N/A | Oligodeoxy-nucleotide hybridisation of DNA amplified by PCR | 5/15 (33) vs 5/15 (33) [present in multiple metastatic sites] | 15/15 (100) |
(ii) 13/15 (87) | ADC: 6 | [Concurrent] | |||||||
(iii) [Spain] | SSC: 4 | ||||||||
(iv) Never-smoker: 1/15 (7); ever-smoker: 14/15 (93) | SCC: 3 | ||||||||
LCC: 2 |